Evercore Notes AbbVie Inc.'s (ABBV) Tremfya Gains Market Share, But Future Earnings Growth May Be Limited

AbbVie Inc. (NYSE:ABBV) is among the 7 Most Promising Psychedelic Stocks According to Hedge Funds.

AbbVie Inc. (NYSE:ABBV) tops our list for being one of the most promising stocks.

TheFly reported on February 4 that Evercore ISI lowered its price target on ABBV to $228 from $232 and maintained an Outperform rating. The firm noted that although Tremfya is gaining market share, AbbVie’s 2026 guidance and current consensus estimate still appear achievable, with similar expectations for 2027. But Evercore said that buy-side projections have been outpacing consensus for a while, which may limit the size of future earnings gains. The company went on to say that investor concerns are becoming more focused on AbbVie's growth trajectory after 2028, especially as more rival treatments are anticipated to hit the market.

Additionally, AbbVie Inc. (NYSE:ABBV) reported full-year adjusted EPS of $10 on the same day that it closed 2025 with record performance, above its initial guidance midpoint by $0.54 (excluding IPR&D expenses). Overall sales increased 8.6% year over year despite a significant U.S. Humira decline, and total net revenue reached $61.2 billion, more than $2 billion above initial expectations.

In order to expand its pipeline across immunology, oncology, neuroscience, and obesity, the company completed almost $5 billion in business development deals, advanced about 90 clinical studies, and boosted adjusted R&D investment by almost $1 billion.

ABBV anticipates a 9.5% increase in overall revenues in 2026, mainly due to Skyrizi and Rinvoq, which are expected to generate a combined revenue of over $31 billion, surpassing previous long-term expectations.

Abbvie Inc. (NYSE:ABBV) is a global biopharmaceutical company expanding into psychedelic-inspired mental health treatments by acquiring and developing novel compounds like bretisilocin for major depressive disorder and partnering on next-gen neuroplastogen research, signaling strategic innovation beyond its traditional therapies into emerging psychiatric medicine.

While we acknowledge the potential of ABBV as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you’re looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the

Disclosure: None.